Tumor heterogeneity in response to therapy and its association with outcome in patients with metastatic colorectal cancer (mCRC)

被引：0
|
作者：
Liu, Junjia [1 ]
Xie, Hao [2 ]
机构：
[1] Albert Einstein Coll Med, Bronx, NY USA
[2] H Lee Moffitt Canc Ctr Res Inst, Tampa, FL USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5255
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Beyond PERCIST: prognostic impact of tumor response heterogeneity in metastatic colorectal cancer (mCRC).
    Flamen, Patrick
    Garcia, Camilo
    Woff, Erwin
    Guiot, Thomas
    Ameye, Lieveke
    Muteganya, Raoul
    Hendlisz, A.
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (03)
  • [2] Temporospatial heterogeneity in metastatic colorectal cancer (mCRC)
    Fountzilas, C.
    Witkiewicz, A.
    Muhitch, J.
    Abrams, S.
    Knudsen, E.
    Mukherjee, S.
    Bajor, D.
    Saltzman, J.
    Wang, K.
    Iyer, R.
    Kalinski, P.
    Boland, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S1458 - S1458
  • [3] PET AS A PREDICTOR OF METABOLIC RESPONSE TO ANTIANGIOGENIC THERAPY IN METASTATIC COLORECTAL CANCER (MCRC)
    Van Damme, Nancy
    De Bruyne, Sylvie
    Ferdinande, Liesbeth
    Ceelen, Wim
    Mertens, Jeroen
    Van de Wiele, Christophe
    Laurent, Stephanie
    Smeets, Peter
    Geboes, Karen
    Peeters, Marc
    ANNALS OF ONCOLOGY, 2011, 22 : v92 - v92
  • [4] Comorbidities in patients with metastatic colorectal cancer (mCRC)
    Fu, A. Z.
    Zhao, Z.
    Wang, P. F.
    Barber, B.
    Liu, G. G.
    EJC SUPPLEMENTS, 2009, 7 (02): : 339 - 339
  • [5] Tumor burden (TB) as a prognostic indicator in patients with metastatic colorectal cancer (mCRC).
    Loh, Kiley Wei Jen
    Shapiro, Jeremy David
    Tran, Ben
    Wong, Hui-Li
    Wong, Shu Fen
    Richardson, Gary Edward
    Harold, Michael
    Gibbs, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [6] Tumor Response-speed Heterogeneity as a Novel Prognostic Factor in Patients With Metastatic Colorectal Cancer
    Liu, Junjia
    Wang, Xuefeng
    Sahin, Ibrahim H.
    Imanirad, Iman
    Felder, Seth I.
    Kim, Richard D.
    Xie, Hao
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2023, 46 (02): : 50 - 57
  • [7] Treatment with bevacizumab in patients with metastatic colorectal cancer (mCRC)
    Ocvirk, Janja
    Rebersek, Martina
    Boc, Marko
    Motara, Maja Ebert
    Mesti, Tanja
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Tumor Microenvironment in Metastatic Colorectal Cancer: The Arbitrator in Patients' Outcome
    Galindo-Pumarino, Cristina
    Collado, Manuel
    Herrera, Mercedes
    Pena, Cristina
    CANCERS, 2021, 13 (05) : 1 - 29
  • [9] BRCA mutations in metastatic colorectal cancer (mCRC) and response to chemotherapy
    Feng, Sophie
    Al-Showbaki, Laith
    Krzyzanowska, Monika K.
    Prince, Rebecca M.
    Stockley, Tracy
    Yu, Celeste
    Bedard, Philippe L.
    Siu, Lillian L.
    Chen, Eric Xueyu
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [10] Response to pembrolizumab in patients with mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).
    Leal, Alexis Diane
    Paludo, Jonas
    Finnes, Heidi D.
    Grothey, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
12345